A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

PHASE3

Phase

RECRUITING

Status

930

Enrollment

INDUSTRY

Sponsor class

Conditions

DRUG: Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24
DRUG: Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24
OTHER: Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24

Ocular Therapeutix, Inc.